Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 6, Issue 2, 2001, Pages 137-145

  Siekmeier, R ^a,b   Lattke, P ^a   Mix, C ^a   Park, J W ^c   Jaross, W ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

^c Freital Hospital   (Germany)

Author keywords

Fluvastatin; High performance liquid chromatography; HMG CoA reductase inhibitor; Hypercholesterolemia

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; DEVICE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; MALE; NORMAL HUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STATISTICAL ANALYSIS;

ADMINISTRATION, ORAL; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS;

EID: 0034763265     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840100600205     Document Type: Article

References (26)

1. Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease
2. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES study)
3. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
5. Clinical pharmacokinetics of fluvastatin with reference to other HMG-CoA reductase inhibitors
6. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors
7. Biotransformation of fluvastatin sodium in humans
8. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
9. Jejunal permeability and hepatic extraction of fluvastatin in humans
10. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors
11. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isoenzymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
12. High-performance liquid chromatographic method for the determination of fluvastatin in human plasma
13. Determination of fluvastatin enantiomers and the racemate in human blood plasma by liquid chromatography and fluorometric detection
14. Liquid chromatographic determination of fluvastatin and its enantiomers in blood plasma by automated solid-phase extraction
15. Clinical pharmacokinetics of fibric acid derivatives (Fibrates)
16. Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients
17. Determination of pravastatin in human plasma by high-performance liquid chromatography with ultraviolet detection
18. Determination of pravastatin by high performance liquid chromatography
19. High-performance liquid chromatography determination of pravastatin in plasma
20. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers
21. Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation?
22. Permeability of small nonelectrolytes through lipid bilayer membranes
23. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues
24. Hepatocyte selectivity of HMG-CoA reductase inhibitors
25. Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver
26. Hepatoselective carrier-mediated sodium-independent uptake of pravastatin and pravastatin-lactone